MarketResearchFuture.com published a Half-Cooked research report on “Global Tendinitis Treatment Market Research Report – Forecast to 2023” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023.
TRY FREE SAMPLE REPORT @ https://www.marketresearchfuture.com/sample_request/3876 .
Global tendinitis treatment market is expected to grow at the CAGR of ~3.8% during the forecast period and is estimated to reach USD 426.4 million by 2023.
The recent market developments has necessitated a ‘see through’ approach so as to avoid the slippery slope generated by the changing paradigms resulting from the powerful forces of economy, business models, competition and others. “Market Research future” presents its latest report titled “World Tendinitis Treatment Market –forecast till 2023” to help clear the blur resulting from these developments and to give the reader a clear picture of the possibilities and nuisances lying ahead!
Global Tendinitis Treatment Market – Regional Analysis:
Considering the global scenario of the tendinitis treatment market, there are four main regions, the Americas, Europe, Asia Pacific, and Middle East and Africa.
The Americas is dominating region in global tendinitis treatment market. North America is highest revenue generator and important contributor in this market. Advance treatment facilities and fast adoption of new therapies are driving growth for this market. Europe is the second largest market for tendinitis treatment. Increasing cases of sport injuries and availability of products as well as treatment options are driving the growth for European tendinitis market. The western European countries like Germany, France and UK are holding the largest market share while Eastern European region is also growing at steady pace. The rapid growth of healthcare sector and increasing spending on health related problems are some of the driving factors for the growth of Asia Pacific tendinitis treatment market. Middle East and Africa market is growing slower than the global average. Middle Eastern region is growing significantly as compared to
Global Tendinitis Treatment Market – Key Players:
Almatica Pharma, Inc. (US), AstraZeneca (US), Bayer (Germany), Boehringer Ingelheim Pharmaceuticals, Inc. (US), Merck & Co., Inc (US), Pfizer (US), and others are some of the prominent players at the forefront of competition in the Global Tendinitis Treatment Market and are profiled in MRFR Analysis.
Global Tendinitis Treatment Market – Overview:
Tendinitis is the inflammation of the tendon, thick cords that attach the muscles to the bone. The inflammation occurs as a result of sudden injury to the tendon, repetitive movement or disease condition such as diabetes, rheumatoid arthritis, gout, Reiter’s syndrome or lupus. In case of patients with gout, the uric acid crystals appear in the tendon sheath leading to friction. Tendinitis is found to be prevalent among athletes and is one of the common sport injuries in sport players, especially tennis, golf and others. Various pharmacological and non-pharmacological treatments are available for the treatment of tendinitis. Non-steroidal anti-inflammatory drugs (NSAIDs) constitute the preliminary treatment options. Other treatments including physical therapy, rest, and occupational therapy. Surgery is the last resort for tendinitis, and is only recommended in case of severe damage to the tendon that cannot be treated using pharmacological treatment options.
Rising prevalence of sport injuries has spurred the growth of this market. According to the U.S. centers for diseases control, around 10% of kids and teen participating in the sports suffer from minor or major type of injury. Moreover, increasing geriatric population, and growing prevalence diabetes and rheumatoid arthritis are import factors accelerating the growth of the market. Rising awareness about sport injuries, and growing emphasis on early diagnosis and treatment of sport injuries also influence the market growth. Additionally, availability of skilled healthcare professionals in the field of sports medicine is another important factor driving the market. However, use of pain reliever or OTC drugs may result in side effects, restraining the growth of the market.
Global tendinitis treatment market is expected to grow at the CAGR of ~3.8% during the forecast period and is estimated to reach USD 426.4 million by 2023. According to a recent study report published by the Market Research Future, the global tendinitis treatment market is expected to gain eminence over the forecast period. The market is forecasted to demonstrate a steady growth by 2023, surpassing its previous growth records in terms of value with a constant CAGR during the anticipated period (2017 – 2023).
Global Tendinitis Treatment Market – Competitive Analysis:
The market for tendinitis treatment is characterised by the presence of several well-established and small players, the global market of tendinitis treatment appears to be highly competitive and fragmented. Major players are increasingly expanding their footprint in the emerging nations, making it putting pressure on the regional players, especially in terms of features such as type, product portfolios, and pricing. The market is witnessing intensified competition which is expected to get more intensified further during the forecast period. The tendinitis treatment market appears to be highly competitive owing to the presence of several large and small key players accounting for a substantial market share. Many leading players are concentrated in the Americas owing to well-established market and high healthcare expenditures; these players have expanded their market in other region as well. Furthermore, the companies such as Abbott, AstraZeneca, Teva, and Pfizer are well-established in European market. The major four players namely Abbott, AstraZeneca, Teva, and Pfizer accounted for more than 17% share of the Americas and Europe tendinitis market.
In April 2017, Pfizer entered into a merger with Allergan to gain access for Allergan’s portfolio including Botox, Viagra, the Prevnar pneumonia vaccine, and treatments for ailments including Alzheimer’s and rheumatoid arthritis.
Furthermore, in July 2017, Merck & Co.Inc & AstraZeneca entered into strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s LYNPARZA (olaparib) for multiple cancer types.
Furthermore, in November 2016, AstraZeneca announced a licensing agreement between MedImmune, its global biologics research and development arm, and Allergan plc, for the global rights to MEDI2070.
Moreover, May 2014, the company acquired Merck & Co., Inc.’s non-prescription business to become the OTC leader in North America and Latin America & achieve top global positions in key OTC product categories.
Therefore, the growing key business strategies will help the key competitors to expand their presence in various parts of the globe for their competitive products and will has spurred the growth of the market.
AVAIL AMAZING DISCOUNT ON REPORT @ https://www.marketresearchfuture.com/check-discount/4980 .
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312